Similar articles

• Thyrotropin releasing hormone (TRH): DOPA potentiation and biogenic amine studies.

  Plotnikoff NP, Breese GR, Prange AJ. Plotnikoff NP, et al. Pharmacol Biochem Behav. 1975 Jul-Aug;3(4):665-70. doi: 10.1016/0091-3057(75)90189-6. Pharmacol Biochem Behav. 1975. PMID: 810812
• Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.

  Voith K. Voith K. Arzneimittelforschung. 1977;27(12):2290-3. Arzneimittelforschung. 1977. PMID: 23795
• Effects of the tripeptides TRH, MIF and MAF on the cerebral dopaminergic system.

  Klusha B, Georgiev V, Petkov V, Markovska V. Klusha B, et al. Acta Physiol Pharmacol Bulg. 1983;9(2):14-9. Acta Physiol Pharmacol Bulg. 1983. PMID: 6140814
• Behavioral effects of hypothalamic releasing hormones in animals and men.

  Prange AJ Jr, Wilson IC, Breese GR, Lipton MA. Prange AJ Jr, et al. Prog Brain Res. 1975;42:1-9. doi: 10.1016/S0079-6123(08)63636-5. Prog Brain Res. 1975. PMID: 729 Review. No abstract available.
• Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.

  Mishra RK, Chiu S, Chiu P, Mishra CP. Mishra RK, et al. Methods Find Exp Clin Pharmacol. 1983;5(4):203-33. Methods Find Exp Clin Pharmacol. 1983. PMID: 6136640 Review. No abstract available.